Polyphase wireless power transfer system achieves 270-kilowatt charge, s...
For years Brenda Smith found fulfillment working with nuclear batteries, a topic she’s been researching as a chemist at Oak Ridge National Laboratory.
At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.
Toward the goal of bringing the next generation of nuclear power reactor technology online this decade, ORNL and Analysis and Measurement Services Corporation have successfully completed loop testing of instrument and control sensors for an advanced reactor design for small modular reactors.
The U.S. Department of Energy’s Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program is seeking proposals for high-impact, computationally intensive research campaigns in a broad array of science, engineering and computer science domains.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
When COVID-19 was declared a pandemic in March 2020, Oak Ridge National Laboratory’s Parans Paranthaman suddenly found himself working from home like millions of others.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.